NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $345.78 -4.78 (-1.36%) As of 01:55 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Praxis Precision Medicines Stock (NASDAQ:PRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PRAX alerts:Sign Up Key Stats Today's Range$345.04▼$353.0050-Day Range$276.44▼$350.5652-Week Range$35.21▼$358.76Volume124,444 shsAverage Volume449,174 shsMarket Capitalization$9.64 billionP/E RatioN/ADividend YieldN/APrice Target$592.67Consensus RatingModerate Buy Company Overview Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders. The company’s pipeline includes several lead candidates at various stages of development. PRAX-562 is a selective persistent sodium current inhibitor being evaluated for severe epilepsies and other hyperexcitability disorders. PRAX-944, a T-type calcium channel blocker, is under investigation for essential tremor. PRAX-114, a neuroactive steroid that modulates GABAA receptors, is in development for major depressive disorder and postpartum depression. Additional programs, such as PRAX-330 and early research efforts targeting novel ion channel subtypes, further expand the company’s therapeutic reach. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis Precision Medicines conducts preclinical and clinical research primarily in the United States, with clinical trial sites across North America and Europe. The company has built a platform that integrates genetic discovery, patient stratification and biomarker development to accelerate the translation of scientific findings into targeted treatments. By collaborating with academic institutions and leveraging external partnerships, Praxis aims to optimize its clinical strategy and deliver data-driven insights for regulatory interactions. Leadership at Praxis includes Winston W. Yen, M.D., co-founder and Chief Executive Officer, who brings experience in neuroscience drug development, and a management team with expertise spanning medicinal chemistry, clinical development and regulatory affairs. The company’s governance and scientific advisory board feature experts in neurology, genetics and drug discovery, supporting a strategy focused on precision medicine for CNS diseases.AI Generated. May Contain Errors. Read More Praxis Precision Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScorePRAX MarketRank™: Praxis Precision Medicines scored higher than 61% of companies evaluated by MarketBeat, and ranked 357th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 4 strong buy ratings, 13 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialPraxis Precision Medicines has a consensus price target of $592.67, representing about 70.4% upside from its current price of $347.88.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($14.79) to ($10.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -26.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -26.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 6.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.92% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 9.35.Change versus previous monthShort interest in Praxis Precision Medicines has recently decreased by 0.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.04 News SentimentPraxis Precision Medicines has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Praxis Precision Medicines this week, compared to 7 articles on an average week.Search Interest9 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by Insiders2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRAX Stock News HeadlinesPraxis Precision Medicines' (PRAX) Buy Rating Reaffirmed at BTIG ResearchMay 21 at 3:15 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesMay 19 at 2:22 AM | americanbankingnews.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 22 at 1:00 AM | Behind the Markets (Ad)Is FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)?May 18, 2026 | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $715.00 at Truist FinancialMay 14, 2026 | americanbankingnews.comPraxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comWedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)May 11, 2026 | insidermonkey.comHC Wainwright Has Negative Outlook of PRAX FY2030 EarningsMay 11, 2026 | americanbankingnews.comSee More Headlines PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $294.74 at the beginning of 2026. Since then, PRAX shares have increased by 18.0% and is now trading at $347.8750. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($3.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.58) by $0.38. Read the conference call transcript. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines shares reverse split on Wednesday, November 29th 2023.The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $170 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' top institutional investors include Janus Henderson Group PLC (12.41%), Bank of America Corp DE (1.92%), Vivo Capital LLC (1.22%) and Pictet Asset Management Holding SA (1.03%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola, Marcio Souza and Jill Desimone. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Praxis Precision Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/22/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PRAX's financial health is in the Green zone, according to TradeSmith. PRAX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRAX CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees110Year Founded2015Price Target and Rating Average Price Target for Praxis Precision Medicines$592.67 High Price Target$1,245.00 Low Price Target$83.00 Potential Upside/Downside+70.4%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($13.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$303.27 million Net MarginsN/A Pretax Margin-3,658.53% Return on Equity-43.02% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio15.88 Quick Ratio15.88 Sales & Book Value Annual Sales$8.55 million Price / Sales1,134.03 Cash FlowN/A Price / Cash FlowN/A Book Value$50.58 per share Price / Book6.88Miscellaneous Outstanding Shares27,880,000Free Float27,126,000Market Cap$9.70 billion OptionableOptionable Beta2.76 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PRAX) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
